PAX5 (Paired Box 5)

Ultimately, the patient was diagnosed with fluid overload-associated large B-cell lymphoma and treated with rituximab, cyclophosphamide, vincristine sulfate, and prednisone, but passed away three months after diagnosis. It may be mistaken for other conditions such as primary effusion lymphoma or other diffuse large B-cell lymphomas. The presence of a Human Herpesvirus-8-negative effusion-based lymphoma in an elderly immunocompetent patient without nodal or tissue involvement should prompt consideration of fluid overload-associated large B-cell lymphoma.

P3, N=635, Active, not recruiting, Acerta Pharma BV | Trial completion date: Oct 2025 --> Feb 2027 | Trial primary completion date: Oct 2025 --> Feb 2027

Mechanistically, Cd72+/-;Pax5+/- precursor B cells exhibit an inflammatory transcriptional profile characterized by a decrease in Myd88 expression, a finding that aligns with our previous studies of B-ALL development in Pax5+/- mice following exposure to immune stressors. These combined genomic analyses and functional models provide compelling evidence that co-deletion of two contiguous genes, Pax5 and Cd72, drives B-cell leukemogenesis.

While single cases of similar composite neoplasms have been reported in humans, this is the first documented case in a laboratory mouse. These findings expand the known spectrum of spontaneous hematopoietic tumours in aged mice and highlight the importance of comprehensive histopathological and immunophenotypic evaluation in diagnosing atypical lesions.

The B-ALL patients with concurrent RB1 and IKZF1 deletions had worse outcomes compared to cases without any of these deletions. The RB1 deletion increased the risk of early events in patients with the IKZF1plus profile.

BIA-DLBCL is an increasingly reported entity which in most cases can be classified within the spectrum of fibrin-associated large B-cell lymphoma (FA-LBCL). While surgical excision alone may be sufficient for localized disease, the rarity of this lymphoma highlights the urgent need for more comprehensive data, particularly long-term survival outcomes, to refine classification and therapeutic recommendations.

Additionally, the integration of IKZF1 deletion status into risk stratification models revealed markedly different survival outcomes, highlighting its potential interest in developing new stratification algorithms. These results underscore the critical importance of molecular profiling, particularly IKZF1 status, for improving outcomes in ALL patients in Tunisia.

P1/2, N=27, Recruiting, OHSU Knight Cancer Institute | Not yet recruiting --> Recruiting

The histomorphologic and immunohistochemical features of the histiocytic sarcoma in this Lemur catta were characteristic of this condition in other species. This report documents the first case of histiocytic sarcoma in Lemur catta, providing novel histopathological and immunohistochemical insights of this condition in prosimians.

Immunohistochemistry showed atypical large mononuclear cells positive to Pax5 (neoplastic B cells) and abundant small round cells positive to CD3 (reactive T cells), confirming the diagnosis of central nervous system T-cell-rich B-cell lymphoma with an angiocentric and angioinvasive distribution pattern. This article describes imaging characteristics of a rare case of histopathologically confirmed central nervous system T-cell-rich B-cell lymphoma.

Neoplastic cells were immunoreactive for CD3 and not for PAX-5. The final diagnosis was Sézary syndrome arising from cutaneous epitheliotropic T-cell lymphoma resembling human folliculotropic mycosis fungoides.

Our approach provides a systematic method to identify precision oncology targets based on expression-driven dependency patterns. By integrating multi-omics data with genetic dependency screens, we've created a comprehensive catalog of potential therapeutic targets that may expand treatment options for cancer patients lacking druggable mutations. This resource offers new opportunities for precision oncology target discovery beyond mutation-based approaches.